esophageal cancer
Conditions
Interventions
C+CRT:conventional two-dimensional radiotherapy combined with three-dimensional conformal radiotherapy
Group 2:WCCRT treatment
Sponsors
Clinical oncology center of the 105th Hospital of PLA
Eligibility
Sex/Gender
All
Age
30 Years to 88 Years
Inclusion criteria
Inclusion criteria: 1. Histological or cytologic diagnosis of esophageal squamous carcinoma; 2. KPS = 70; 3. Aged 18-85 years; 4. Joined the study voluntarily and signed informed consent form; 5. Not have received any prior anticancer therapy; advanced esophageal cancer (T2-4N0-1M0-1a, TxN1M0-1a, TxNxM1a, AJCC 6th); 6. No serious system dysfunction and immuno-deficiency, Adequate organ function including the following: Hemoglobin =9 g/dL, WBC=3x10^9/L, Neutrophils (ANC )=1.5x10^9/L, platelet count =100x 10^9/L, TBIL<1.5 x ULN, ALT and AST ? 2.5 x ULN, creatinine ? 1.5 x ULN; 7. Use of an effective contraceptive for adults to prevent pregnancy; 8. Life expectancy of more than 3 months. ;Inclusion criteria: 1. Histological or cytologic diagnosis of esophageal squamous carcinoma; 2. KPS = 70; 3. Aged 18-85 years; 4. Joined the study voluntarily and signed informed consent form; 5. Not have received any prior anticancer therapy; advanced esophageal cancer (T2-4N0-1M0-1a, TxN1M0-1a, TxNxM1a, AJCC 6th); 6. No serious system dysfunction and immuno-deficiency, Adequate organ function including the following: Hemoglobin =9 g/dL, WBC=3x10^9/L, Neutrophils (ANC )=1.5x10^9/L, platelet count =100x 10^9/L, TBIL<1.5 x ULN, ALT and AST ? 2.5 x ULN, creatinine ? 1.5 x ULN; 7. Use of an effective contraceptive for adults to prevent pregnancy; 8. Life expectancy of more than 3 months. ;Inclusion criteria: 1. Histological or cytologic diagnosis of esophageal squamous carcinoma; 2. KPS = 70; 3. Aged 18-85 years; 4. Joined the study voluntarily and signed informed consent form; 5. Not have received any prior anticancer therapy; advanced esophageal cancer (T2-4N0-1M0-1a, TxN1M0-1a, TxNxM1a, AJCC 6th); 6. No serious system dysfunction and immuno-deficiency, Adequate organ function including the following: Hemoglobin =9 g/dL, WBC=3x10^9/L, Neutrophils (ANC )=1.5x10^9/L, platelet count =100x 10^9/L, TBIL<1.5 x ULN, ALT and AST ? 2.5 x ULN, creatinine ? 1.5 x ULN; 7. Use of an effective contraceptive for adults to prevent pregnancy; 8. Life expectancy of more than 3 months. ;Inclusion criteria: 1. Histological or cytologic diagnosis of esophageal squamous carcinoma; 2. KPS = 70; 3. Aged 18-85 years; 4. Joined the study voluntarily and signed informed consent form; 5. Not have received any prior anticancer therapy; advanced esophageal cancer (T2-4N0-1M0-1a, TxN1M0-1a, TxNxM1a, AJCC 6th); 6. No serious system dysfunction and immuno-deficiency, Adequate organ function including the following: Hemoglobin =9 g/dL, WBC=3x10^9/L, Neutrophils (ANC )=1.5x10^9/L, platelet count =100x 10^9/L, TBIL<1.5 x ULN, ALT and AST ? 2.5 x ULN, creatinine ? 1.5 x ULN; 7. Use of an effective contraceptive for adults to prevent pregnancy; 8. Life expectancy of more than 3 months. ;Inclusion criteria: 1. Histological or cytologic diagnosis of esophageal squamous carcinoma; 2. KPS = 70; 3. Aged 18-85 years; 4. Joined the study voluntarily and signed informed consent form; 5. Not have received any prior anticancer therapy; advanced esophageal cancer (T2-4N0-1M0-1a, TxN1M0-1a, TxNxM1a, AJCC 6th); 6. No serious system dysfunction and immuno-deficiency, Adequate organ function including the following: Hemoglobin =9 g/dL, WBC=3x10^9/L, Neutrophils (ANC )=1.5x10^9/L, platelet count =100x 10^9/L, TBIL<1.5 x ULN, ALT and AST ? 2.5 x ULN, creatinine ? 1.5 x ULN; 7. Use of an effective contraceptive for adults to prevent pregnancy; 8. Life expectancy of more than 3 months.
Exclusion criteria
Exclusion criteria: 1. Pregnancy woman; 2. Complicated with acute infections, severe acute infection, suppurative and chronic infection, or the inpatient of the wound; 3. esophageal perforation (esophageal tracheal fistula or patients who may have esophageal tracheal fistulas) with clear symptoms and multiple distant metastases; 4. Received other anti-tumor treatment before enrollment; 5. coagulant function abnormal, have bleeding tendency (such as active peptic ulcer), or disease in accepting thrombolytic or anticoagulant therapy; 6. original serious heart disease, including: congestive heart failure, high-risk sexual beyond the control of the rhythm of the heart failure, unstable angina, half a year of myocardial infarction, severe valvular heart disease, and resistant hypertension; 7. patients with uncontrollable nerve, mental illness, or mental disorders, depending on the sex, cannot cooperation and adverse response for descriptive treatment; 8. severe liver cirrhosis, severe kidney dysfunction. ;Exclusion criteria: 1. Pregnancy woman; 2. Complicated with acute infections, severe acute infection, suppurative and chronic infection, or the inpatient of the wound; 3. esophageal perforation (esophageal tracheal fistula or patients who may have esophageal tracheal fistulas) with clear symptoms and multiple distant metastases; 4. Received other anti-tumor treatment before enrollment; 5. coagulant function abnormal, have bleeding tendency (such as active peptic ulcer), or disease in accepting thrombolytic or anticoagulant therapy; 6. original serious heart disease, including: congestive heart failure, high-risk sexual beyond the control of the rhythm of the heart failure, unstable angina, half a year of myocardial infarction, severe valvular heart disease, and resistant hypertension; 7. patients with uncontrollable nerve, mental illness, or mental disorders, depending on the sex, cannot cooperation and adverse response for descriptive treatment; 8. severe liver cirrhosis, severe kidney dysfunction. ;Exclusion criteria: 1. Pregnancy woman; 2. Complicated with acute infections, severe acute infection, suppurative and chronic infection, or the inpatient of the wound; 3. esophageal perforation (esophageal tracheal fistula or patients who may have esophageal tracheal fistulas) with clear symptoms and multiple distant metastases; 4. Received other anti-tumor treatment before enrollment; 5. coagulant function abnormal, have bleeding tendency (such as active peptic ulcer), or disease in accepting thrombolytic or anticoagulant therapy; 6. original serious heart disease, including: congestive heart failure, high-risk sexual beyond the control of the rhythm of the heart failure, unstable angina, half a year of myocardial infarction, severe valvular heart disease, and resistant hypertension; 7. patients with uncontrollable nerve, mental illness, or mental disorders, depending on the sex, cannot cooperation and adverse response for descriptive treatment; 8. severe liver cirrhosis, severe kidney dysfunction. ;Exclusion criteria: 1. Pregnancy woman; 2. Complicated with acute infections, severe acute infection, suppurative and chronic infection, or the inpatient of the wound; 3. esophageal perforation (esophageal tracheal fistula or patients who may have esophageal tracheal fistulas) with clear symptoms and multiple distant metastases; 4. Received other anti-tumor treatment before enrollment; 5. coagulant function abnormal, have bleeding tendency (such as active peptic ulcer), or disease in accepting thrombolytic or anticoagulant therapy; 6. original serious heart disease, including: congestive heart failure, high-risk sexual beyond the control of the rhythm of the heart failure, unstable angina, half a year of myocardial infarction, severe valvular heart disease, and resistant hypertension; 7. patients with uncontrollable nerve, mental illness, or mental disorders, depending on the sex, cannot cooperation and adverse response for descriptive treatment; 8. severe liver cirrhosis, severe kidney dysfunction. ;Exclusion criteria: 1. Pregnancy woman; 2. Complicated with acute infections, severe acute infection, suppurative and chronic infection, or the inpatient of the wound; 3. esophageal perforation (esophageal tracheal fistula or patients who may have esophageal tracheal fistulas) with clear symptoms and multiple distant metastases; 4. Received other anti-tumor treatment before enrollment; 5. coagulant function abnormal, have bleeding tendency (such as active peptic ulcer), or disease in accepting thrombolytic or anticoagulant therapy; 6. original serious heart disease, including: congestive heart failure, high-risk sexual beyond the control of the rhythm of the heart failure, unstable angina, half a year of myocardial infarction, severe valvular heart disease, and resistant hypertension; 7. patients with uncontrollable nerve, mental illness, or mental disorders, depending on the sex, cannot cooperation and adverse response for descriptive treatment; 8. severe liver cirrhosis, severe kidney dysfunction.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS; | — |
Countries
China
Contacts
Public ContactDonglai Lv;Donglai Lv;Donglai Lv;Donglai Lv;Donglai Lv ;;;;
The 105th Hospital of People Liberation Army;The 105th Hospital of People Liberation Army;The 105th Hospital of People Liberation Army;The 105th Hospital of People Liberation Army;The 105th Hospital of People Liberation Army
Outcome results
None listed